While several trials utilizing anti-PD-1 or anti-programmed cell death-ligand 1 (PD-L1) are currently ongoing in patients with initial GBM (15), whether the specific features of recurrent GBM create unique immune changes and exhibit differences in their immune microenvironment remain unclear. This evidence concerns the gene PDCD1 and glioblastoma.